facebook
twitter
search
search

Wyeth's Prevnar sales booming

Nov. 4, 2004 at 1:10 PM

CHICAGO, Nov. 4 (UPI) -- Prevnar, the popular drug to prevent bacterial meningitis, is on course to make more than $1 billion this year, a report says.

Sales of Prevnar, made by the pharmaceutical giant Wyeth, soared 32 percent in the third quarter to $321 million, the Chicago Tribune said Thursday.

A recent financial statement indicated this came about in part because the company made upgrades and improvements to its manufacturing facilities over the last year.

Prevnar vaccine costs about $260 for the four-shot regimen given to infants and young children. A dose of flu vaccine, by contrast, fetches about $8.

Wyeth left the flu vaccine market entirely last year to focus resources on its more lucrative vaccine.

Latest Headlines
Top Stories
Australia receives seventh C-17 in record time
Crude oil prices extend losses
Greenpeace again stands in Shell's way to arctic
Work to prepare Portsmouth Navy base for new carriers begins
Saudis to acquire hundreds of advanced Patriot missiles